CDK10 Is Not a Target for Aberrant DNA Methylation in Breast Cancer

被引：0
|
作者：
Heller, Gerwin
Ziegler, Barbara
Brandstetter, Anita
Novak, Sabine
Rudas, Margaretha [2 ]
Hennig, Guido [3 ]
Gehrmann, Mathias [3 ]
Acht, Torsten [3 ]
Zoechbauer-Mueller, Sabine
Filipits, Martin [1 ]
机构：
[1] Med Univ Vienna, Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Pathol, A-1090 Vienna, Austria
[3] Siemens Healthcare Diagnost Prod GmbH, Mol Res Germany, D-50829 Cologne, Germany
来源：
ANTICANCER RESEARCH | 2009年 / 29卷 / 10期
关键词：
Breast cancer; CDK10; tamoxifen; DNA methylation; cyclin-dependent kinase; CYCLIN D1; ESTROGEN-RECEPTOR; PROMOTER METHYLATION; ADJUVANT TAMOXIFEN; ENDOCRINE THERAPY; RESISTANCE; OVEREXPRESSION; EXPRESSION; CELLS; LUNG;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Loss of cyclin-dependent kinase (CDK) 10 expression may be an important mechanism of tamoxifen resistance and the 5' CpG island associated with the CDK10 gene has been suggested to be a target for aberrant methylation in breast cancer. Patients and Methods: The methylation status. of CDK10, RASSFIA (Ras association domain family 1A) and DAL-1 (differentially expressed in adenocarcinoma of the lung) was determined by means of methylation-specific PCR (MSP) in the formalin-fixed, paraffin-embedded (FFPE) surgical specimens of 96 breast carcinoma patients. Reverse transcription kinetic PCR (RT-kPCR) was used for assessment of the expression of CDK10. Results: The unmethylated form of CDK10, RASSFIA and DAL-1 was detected in all the samples analyzed. Methylation of the CDK10 5' region was not found in any of the 96 breast cancer samples. RASSFIA methylation was detected in 75 out of 96 (78%) and DAL-1 in 9 out of 15 (60%) breast cancer samples, respectively. Consistent with the methylation results, the expression of CDK10 was detected in all 96 samples. Conclusion: CDK10 is not a target for aberrant DNA methylation in breast cancer.
引用
收藏
页码：3939 / 3944
页数：6
相关论文
共 50 条
  • [1] Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
    Iorns, Elizabeth
    Turner, Nicholas C.
    Elliott, Richard
    Syed, Nelofer
    Garrone, Ornella
    Gasco, Milena
    Tutt, Andrew N. J.
    Crook, Tim
    Lord, Christopher J.
    Ashworth, Alan
    CANCER CELL, 2008, 13 (02) : 91 - 104
  • [2] CDK10 promotes tumour growth and chemoresistance in colorectal cancer, and is a potential target for treatment
    Weiswald, Louis-Bastien
    Hasan, Mohammad R.
    Rahman, Mahbuba
    Pasiliao, Clarissa
    Tai, Isabella T.
    CANCER RESEARCH, 2015, 75
  • [3] CDK10, a new modulator of the response of breast cancers to tamoxifen?
    Darbon, Jean-Marie
    BULLETIN DU CANCER, 2008, 95 (04) : 393 - 393
  • [4] Aberrant DNA methylation of integrin α4 in human breast cancer
    Do, Sung-Im
    Ko, Eunkyung
    Kang, So Young
    Lee, Jeong Eon
    Nam, Seok Jin
    Cho, Eun Yoon
    Kim, Duk-Hwan
    TUMOR BIOLOGY, 2014, 35 (07) : 7079 - 7084
  • [5] Association of aberrant DNA methylation with clinicopathological features in breast cancer
    Tserga, Aggeliki
    Michalopoulos, Nicolaos V.
    Levidou, Georgia
    Korkolopoulou, Penelope
    Zografos, George
    Patsouris, Efstratios
    Saetta, Angelica A.
    ONCOLOGY REPORTS, 2012, 27 (05) : 1630 - 1638
  • [6] Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?
    Tse, Janson W. T.
    Jenkins, Laura J.
    Chionh, Fiona
    Mariadason, John M.
    TRENDS IN CANCER, 2017, 3 (10): : 698 - 712
  • [7] Human CDK10 gene isoforms
    Sergere, JC
    Thuret, JY
    Le Roux, G
    Carosella, ED
    Leteurtre, F
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 276 (01) : 271 - 277
  • [8] Aberrant DNA Methylation and Prostate Cancer
    Majumdar, Sunipa
    Buckles, Eric
    Estrada, John
    Koochekpour, Shahriar
    CURRENT GENOMICS, 2011, 12 (07) : 486 - 505
  • [9] Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma
    Nakaoka, Toshiaki
    Saito, Yoshimasa
    Saito, Hidetsugu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (06)
  • [10] Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
    Gyorffy, B.
    Bottai, G.
    Fleischer, T.
    Munkacsy, G.
    Paladini, L.
    Bressen-Dale, A. L.
    Kristensen, V.
    Santarpia, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S41 - S41
12345